CCL4 and myeloid sarcoma: In our cohort of patients, having normal (similar to HC) plasma HGF and Eotaxin/CCL11 levels and low plasma EGF and MIP-1β/CCL4 levels were prognostic risk factors for being classified as a progressive patient with MS (SP-MS or PP-MS).